Stockscreener 앱 받기
22.69
3.08%
-0.72
시간 외 거래:
22.50
-0.19
-0.84%
전일 마감가:
$23.41
열려 있는:
$23.14
하루 거래량:
1.18M
Relative Volume:
0.84
시가총액:
$2.79B
수익:
$460.48M
순이익/손실:
$142.80M
주가수익비율:
19.23
EPS:
1.18
순현금흐름:
$221.79M
1주 성능:
-3.49%
1개월 성능:
+6.68%
6개월 성능:
-9.09%
1년 성능:
+2.81%
1일 변동 폭
$22.64
$23.15
1주일 범위
$22.64
$23.92
52주 변동 폭
$19.05
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
명칭
Catalyst Pharmaceuticals Inc
전화
(305) 529-2522
주소
355 ALHAMBRA CIRCLE, CORAL GABLES
CPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
22.69 | 2.88B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.60 | 110.02B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.11 | 82.00B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.56 | 59.61B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
894.90 | 56.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
211.41 | 44.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-04 | 개시 | Robert W. Baird | Outperform |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-03-14 | 개시 | Citigroup | Buy |
| 2024-03-07 | 개시 | BofA Securities | Buy |
| 2023-12-21 | 개시 | Oppenheimer | Outperform |
| 2022-08-24 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-07 | 재개 | Piper Jaffray | Overweight |
| 2016-10-05 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | 재확인 | ROTH Capital | Buy |
| 2014-09-16 | 재확인 | ROTH Capital | Buy |
| 2014-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2013-10-21 | 재확인 | Aegis Capital | Buy |
| 2013-09-24 | 개시 | Maxim Group | Buy |
| 2013-09-06 | 재확인 | Aegis Capital | Buy |
| 2013-04-18 | 개시 | Aegis Capital | Buy |
| 2012-08-27 | 업그레이드 | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | 업그레이드 | Merriman | Sell → Neutral |
| 2009-05-29 | 다운그레이드 | Hapoalim | Neutral → Underperform |
| 2009-05-29 | 다운그레이드 | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | 개시 | Merriman Curhan Ford | Buy |
| 2007-11-28 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | 개시 | Stifel Nicolaus | Buy |
| 2007-01-05 | 개시 | First Albany | Buy |
모두보기
Catalyst Pharmaceuticals Inc 주식(CPRX)의 최신 뉴스
How Do Investors Really Feel About Catalyst Pharmaceuticals Inc? - Benzinga
Wall Street Analysts Think Catalyst (CPRX) Could Surge 47.37%: Read This Before Placing a Bet - Finviz
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock? - Yahoo Finance
Will Catalyst Pharmaceuticals Inc. stock deliver strong dividend growth2025 Market Trends & Consistent Return Strategy Ideas - moha.gov.vn
Will Catalyst Pharmaceuticals Inc. stock see insider buyingGap Down & Weekly High Return Stock Opportunities - BỘ NỘI VỤ
Here's How Much a $1000 Investment in Catalyst Pharmaceutical Made 10 Years Ago Would Be Worth Today - Yahoo Finance
Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference - Bakersfield.com
Will Catalyst Pharmaceuticals Inc. (CN2) stock benefit from sector leadership2025 Investor Takeaways & High Accuracy Swing Entry Alerts - newser.com
Published on: 2025-11-21 01:33:23 - newser.com
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Published on: 2025-11-20 09:43:10 - newser.com
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500 - The Globe and Mail
Published on: 2025-11-20 03:16:30 - newser.com
Why Catalyst Pharmaceuticals Inc. (CN2) stock is trending on social media2025 Buyback Activity & Daily Profit Maximizing Trade Tips - newser.com
Deloitte Fast 500 Ranking Could Be a Game Changer for Catalyst Pharmaceuticals (CPRX) - Sahm
How Catalyst Pharmaceuticals Inc. (CN2) stock stacks up against competitorsWeekly Market Summary & Fast Momentum Stock Entry Tips - newser.com
Relative strength of Catalyst Pharmaceuticals Inc. in sector analysisWeekly Trade Review & Free Technical Confirmation Trade Alerts - newser.com
What analyst consensus says on Catalyst Pharmaceuticals Inc. stockMarket Movers & Proven Capital Preservation Methods - newser.com
Why analysts maintain buy rating on Catalyst Pharmaceuticals Inc. (CN2) stockTrend Reversal & Stepwise Swing Trade Plans - newser.com
Why Catalyst Pharmaceuticals Inc. stock is considered a top pickEarnings Overview Summary & Weekly Top Stock Performers List - newser.com
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock - Yahoo Finance
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™ - The Manila Times
Catalyst Pharmaceuticals (NASDAQ: CPRX) Ranks 304 on 2025 Deloitte Technology Fast 500 - Stock Titan
Published on: 2025-11-19 04:42:53 - newser.com
Is Catalyst Pharmaceuticals Inc. stock attractive for retirement portfoliosInsider Buying & Short-Term Trading Alerts - newser.com
Published on: 2025-11-19 00:40:27 - newser.com
Total assets of Catalyst Pharmaceuticals, Inc. – HAM:CN2 - TradingView
Catalyst Pharmaceuticals Inc (CPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.30%
1.75%
자본화:
|
볼륨(24시간):